# Continued Access to RXDX-105

> **NCT03784378** · PHASE1 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 3 (actual)

## Conditions studied

- Non Small Cell Lung Cancer
- Ovarian Cancer
- RET Gene Mutation
- BRAF Gene Mutation

## Interventions

- **DRUG:** RXDX-105

## Key facts

- **NCT ID:** NCT03784378
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-14
- **Primary completion:** 2020-09-30
- **Final completion:** 2020-09-30
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2025-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03784378

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03784378, "Continued Access to RXDX-105". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03784378. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*